Abstract
Transforming Growth Factor β (TGFβ) signaling influences most aspects of cellular function in addition to playing a major role in organ development, remodeling, and repair. Given the wide range of effects induced by TGFβ, it is not surprising that alterations in TGFβ signaling have been implicated in development and progression of many different cancer types. Within the context of breast cancer itself, TGFβ is known to have a dual nature, being both tumorsuppressive during early breast cancer development and tumor-promoting during breast cancer metastasis. Targets for breast cancer therapeutics are greatly needed to decrease morbidity and mortality from this devastating disease. Here, we summarize what is known about TGFβ in breast cancer progression and discuss potential TGFβ targets for breast cancer therapeutics.
Keywords: Apoptosis, breast cancer, cytostatic, immune regulation, metastasis, stem cell, TGFβ
Current Drug Targets
Title: Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Volume: 11 Issue: 9
Author(s): Sarah E. Baxley and Rosa Serra
Affiliation:
Keywords: Apoptosis, breast cancer, cytostatic, immune regulation, metastasis, stem cell, TGFβ
Abstract: Transforming Growth Factor β (TGFβ) signaling influences most aspects of cellular function in addition to playing a major role in organ development, remodeling, and repair. Given the wide range of effects induced by TGFβ, it is not surprising that alterations in TGFβ signaling have been implicated in development and progression of many different cancer types. Within the context of breast cancer itself, TGFβ is known to have a dual nature, being both tumorsuppressive during early breast cancer development and tumor-promoting during breast cancer metastasis. Targets for breast cancer therapeutics are greatly needed to decrease morbidity and mortality from this devastating disease. Here, we summarize what is known about TGFβ in breast cancer progression and discuss potential TGFβ targets for breast cancer therapeutics.
Export Options
About this article
Cite this article as:
E. Baxley Sarah and Serra Rosa, Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling, Current Drug Targets 2010; 11 (9) . https://dx.doi.org/10.2174/138945010792006771
DOI https://dx.doi.org/10.2174/138945010792006771 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Compounds with Cell Growth Inhibitory Activity in Human Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets Use of Metformin and Survival of Diabetic Women with Breast Cancer
Current Drug Safety Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies in Combination with Radiotherapy in Oesophageal and Gastroesophageal Carcinoma
Current Medicinal Chemistry Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Phage Display Technology and its Applications in Cancer Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance
Current Medicinal Chemistry Editorial [Hot Topic: Modulation, Absorption and Delivery of Xenobiotics: The Synergic Role of CYP450 and P-gp Activities (Guest Editor: Nicola Antonio Colabufo)]
Current Drug Metabolism Tuberculosis Treated by Multiple Drugs: An Overview
Current Drug Delivery Fe-S Proteins Acting as Redox Switch: New Key Actors of Cellular Adaptive Responses
Current Chemical Biology Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design